|
 7th Annual Pharmacovigilance Conference30th - 31st January 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
The importance of Pharmacovigilance has been apparent since the problems with thalidomide emerged in the 1960s. Since then, various high profile drug recalls, and estimations that more than 750,000 injuries and deaths each year in the US are caused by adverse drug reactions, have meant tightened regulatory controls. |
 5th Pharmaceutical Product Lifecycle Management24th - 25th January 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Research shows that pharmaceutical companies spend approximately 19% of their total revenue on activities that fall under the heading of pharmaceutical lifecycle management (PLM). With many blockbuster drugs drawing closer to the end of their patents, R&D new chemical entity output declining and the current economic climate; the utilisation of product lifecycle management is set to increase as pharmaceutical companies look for ways to optimise revenue. |
 5th Annual Recombinant Antibodies17th - 19th January 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
From Kohler and Millstein's pioneering efforts to today's multifactorial approach, monoclonal antibodies have consistently improved the clinical outcome of disease progression. As shown by Avastin and Lucentis, antibodies have blockbuster potential, now number eight of today's 20 top-selling biotech drugs. With ongoing growth rates nearing 15%, the global market will reach $74.7 by 2024 as new approvals and a growing world population drive patient demand. |
 5th Annual Contract Manufacturing7th - 8th December 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
The importance and role of contract manufacturing has changed over the years from solely providing efficiencies in cost, capacity and time-to-market, or a specific expertise not available in-house to unique, innovative, and state-of-the-art processes and production technology to the pharmaceutical industry. |
 4th Annual Biomarkers1st - 2nd December 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Forecasters predict significant growth in the global market of biomarkers with estimates of $26.5 billion by the year 2015. This growth will be driven by the current demand for biomarkers in drug discovery and other areas of R&D. The use of biomarkers during early stages of a product development is already saving costs and time in the industry by indicating the possibility of failure at an earlier stage in the research process. CROs have now recognised the commercial opportunities of biomarkers and are forming partnerships with providers and building in-house capabilities. |
 5th Annual Stability Testing3rd - 4th November 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Pharmaceutical companies are under intense pressure to provide safe, effective medicines for patient consumption while also maintaining adherence to stringent regulatory and quality requirements. Stability testing is a highly integral part of pharmaceutical product development which constitutes one of the fastest growing markets in the pharmaceutical and biotechnology sectors. |
 3rd Annual Vaccine Manufacturing27th - 28th October 2011, Thistle City Barbican, London, UK
The global vaccine market will achieve sustained growth over the next 15 years, and this trend is likely to continue as governments recognise the importance of mass vaccination.
Visiongain's 3rd Annual Vaccine Manufacturing conference will feature key industry experts, who will assess the current landscape of vaccine development and address challenges faced by manufacturers. |
 4th Pre-Filled Syringes17th - 19th October 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS
Join us at Visiongain's 4th Pre-filled syringes conference and gain insight into a spectrum of topical issues ranging from manufacture, formulation and drug identity to quality, safety and novel pre-filled syringe technologies. |
 2nd Annual Cell-Based Assays 201111th - 13th October 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS
It takes well over £500 million and between 10 and 12 years to develop a new drug. For every million compounds screened, approximately 250 make it to pre-clinical testing, 10 advance to clinical trials and just one is approved for patient use. Industry can ill-afford to continue such a wasteful process. |
 9th Biosimilars5th - 7th October 2011, Thistle City Barbican, London, UK
Biopharmaceuticals are an essential therapeutic option accounting for a substantial part of the global therapeutic market. With the patents of many blockbuster drugs coming to an end, an opportunity has arisen for the manufacture and approval of biosimilars. |
|